Form 4: Kezar Life Sciences Director Courtney Wallace Granted Stock Options

Kezar Life Sciences, Inc. Director Courtney Wallace was granted 5,000 stock options with an exercise price of $4.46, vesting fully in June 2026.

Summary

• Courtney Wallace, a Director of Kezar Life Sciences, Inc. (KZR), was granted 5,000 stock options.
• The transaction date for this grant was June 18, 2025.
• Each stock option has an exercise price of $4.46.
• The options will vest 100% on June 18, 2026, contingent upon Ms. Wallace's continued service to the company.
• The expiration date for these stock options is June 17, 2035.
• Following this transaction, Courtney Wallace beneficially owns 5,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a standard insider transaction related to director compensation. While positive for aligning interests, it's a routine event and does not convey significant new positive or negative information about the company's operational or financial performance.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• Equity compensation is a standard practice that helps attract and retain qualified board members.

Negatives

• The options do not provide immediate cash value to the director.
• The value of the options is dependent on the future stock price of Kezar Life Sciences, Inc. exceeding the exercise price.

Risks

• The vesting of the options is subject to the reporting person continuing to provide service through the vesting date (June 18, 2026).
• The value of the stock options is subject to market fluctuations of Kezar Life Sciences, Inc.'s common stock, and may become worthless if the stock price falls below the exercise price.

Future Outlook

The grant of stock options with a future vesting date indicates a long-term incentive structure for the director, aligning their future compensation with the company's performance over time.

Industry Context

The granting of stock options to directors is a common and widely accepted practice in the biotechnology and life sciences industry, as well as across publicly traded companies, to incentivize leadership and align their interests with long-term shareholder value.

Related Party Transactions

• The grant of stock options to Courtney Wallace, a Director of Kezar Life Sciences, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned interests between the director and company performance.
• Director (Courtney Wallace): Receives equity compensation, providing a long-term incentive tied to the company's stock performance.

Next Steps

• Courtney Wallace must continue to provide service to Kezar Life Sciences, Inc. through June 18, 2026, for the stock options to fully vest.

Key Dates

Keywords

Kezar Life Sciences, KZR, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Courtney Wallace